Skip to content
View in the app

A better way to browse. Learn more.

allnurses

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.
Discussion

I'm a new nurse who needs help

I've been working in the ICU for about 3 weeks (just out of nursing school) and I had a patient today who had a GI bleed and hepatic encepalopathy. Pt. was getting Sandostatin and the only effects I have found for that med is that it inhibits growth hormone and insulin, neither of which relate to my patient. Is there some other reason my patient would be getting this that I am not finding? Thanks.

Featured Replies

I've been working in the ICU for about 3 weeks (just out of nursing school) and I had a patient today who had a GI bleed and hepatic encepalopathy. Pt. was getting Sandostatin and the only effects I have found for that med is that it inhibits growth hormone and insulin, neither of which relate to my patient. Is there some other reason my patient would be getting this that I am not finding? Thanks.

You will see this drug used frequently for upper GI bleeding related to portal HTN and liver failure. It produces vasoconstriction along the portal system that can stem bleeding until and during more definitive endoscopic and banding procedures.

http://www.heart-intl.net/HEART/030106/BleedingEsophageal.htm

"Octreotide acetate: Octreotide acetate (Sandostatin) is a synthetic, long-acting analogue of somatostatin (Zecnil). By inhibiting the release of vasodilatory hormones (eg, glucagon), it indirectly causes splanchnic vasoconstriction and decreased portal flow. Several studies found octreotide to be more effective than either placebo or vasopressin in controlling both initial and sustained bleeding (6). Because it has fewer side effects than vasopressin, octreotide has become the drug of choice in the pharmacologic management of acute variceal bleeding. Unfortunately, like vasopressin, it does not increase the survival rate. Octreotide infusion should be started at initial presentation. In most studies, a loading dose of 50 micrograms was given, followed by an infusion of 50 micrograms/hr. Treatment continued through the fifth hospital day following the initial bleeding episode. Definitive endoscopic therapy usually is performed shortly after hemostasis is achieved."

~faith,

Timothy.

  • Author

That is why I love this forum. Thank you very much for your input. I did not get that kind of explanation anywhere I looked online (I don't know where I put my drug book so I couldn't look it up). Thanks again.

That is why I love this forum. Thank you very much for your input. I did not get that kind of explanation anywhere I looked online (I don't know where I put my drug book so I couldn't look it up). Thanks again.

No problem.

~faith,

Timothy.

Guest
This topic is now closed to further replies.

Currently Reading 0

  • No registered users viewing this page.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.